Cerevel Therapeutics' Topline Results From Phase 3 TEMPO-3 Trial For Tavapadon For Parkinson's Disease, Met Primary Endpoint, Demonstrating Statistically Significant Increase In Total "On" Time Without Troublesome Dyskinesia Vs. Placebo
Cerevel Therapeutics' Topline Results From Phase 3 TEMPO-3 Trial For Tavapadon For Parkinson's Disease, Met Primary Endpoint, Demonstrating Statistically Significant Increase In Total "On" Time Without Troublesome Dyskinesia Vs. Placebo
Cerevel Therapeutics 針對帕金森氏病的 Tavapadon 的 3 期 TEMPO-3 試驗的關鍵結果達到了主要終點，表明總體 “上線” 時間與安慰劑
Cerevel Therapeutics' Topline Results From Phase 3 TEMPO-3 Trial For Tavapadon For Parkinson's Disease, Met Primary Endpoint, Demonstrating Statistically Significant Increase In Total "On" Time Without Troublesome Dyskinesia Vs. Placebo
Cerevel Therapeutics 針對帕金森氏病的 Tavapadon 的 3 期 TEMPO-3 試驗的關鍵結果達到了主要終點，表明總體 “上線” 時間與安慰劑
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。